Why the study?
Does a fixed-dose combination of an ACE inhibitor and a beta-blocker improve adherence and outcomes in patients with coronary artery disease?
Does a fixed-dose combination of an ACE inhibitor and a beta-blocker improve adherence and outcomes in patients with coronary artery disease?
Fixed-dose combinations of ACE inhibitors and beta-blockers may improve patient adherence and effectively target neurohumoral activation in coronary artery disease.
Answers are grounded in this paper and cite their sources.
No data address fixed-dose ACE inhibitor-beta-blocker combinations in CAD; leaves open effects on adherence and outcomes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Filip Málek (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: